What is the recommended dosing regimen for liraglutide (including starting dose, weekly titration steps, target and maximum doses) for type 2 diabetes and for obesity treatment?

Liraglutide Dosing Regimen

For type 2 diabetes, initiate liraglutide at 0.6 mg subcutaneously once daily for one week, then increase to 1.2 mg daily, with an optional increase to a maximum of 1.8 mg daily after at least one additional week if glycemic control remains inadequate. 1

Type 2 Diabetes Management

Starting Dose and Titration

• Initial dose: 0.6 mg subcutaneously once daily for one week 1
• Week 2 onward: Increase to 1.2 mg daily 1
• Optional escalation: Increase to 1.8 mg daily after at least one additional week at 1.2 mg if additional glycemic control is needed 1

Administration Details

• Inject subcutaneously once daily at any time of day, independent of meals 1
• Acceptable injection sites include abdomen, thigh, or upper arm 1
• Solution must be clear, colorless, and particle-free before each injection 1
• When using with insulin, administer as separate injections—never mix 1

Key Clinical Considerations

• The weekly dose escalation strategy is specifically designed to improve gastrointestinal tolerability, particularly nausea 2, 3
• Daily blood glucose monitoring is not routinely required, though may be necessary when combined with sulfonylureas due to hypoglycemia risk 2
• If using concomitantly with sulfonylureas, consider reducing the sulfonylurea dose to minimize hypoglycemia risk 2, 3

Obesity Treatment (Weight Management)

Dosing for Obesity

• Starting dose: 0.6 mg subcutaneously daily 4
• Target maintenance dose: 3.0 mg daily 4
• Weekly dose escalation from 0.6 mg up to 3.0 mg for obesity management 5, 6

Weight Loss Outcomes

• At the 3.0 mg dose for obesity, liraglutide produces mean weight loss of approximately 5.8% compared to 1.5% with placebo at 56 weeks 6
• The American Diabetes Association guidelines note that liraglutide 3 mg daily for obesity treatment shows improved waist circumference, blood pressure, and metabolic effects 4

Pediatric Dosing (Ages 10-17 Years)

Type 2 Diabetes in Adolescents

• Initial dose: 0.6 mg subcutaneously once daily for at least one week 1
• Escalation: Increase to 1.2 mg daily if additional glycemic control needed 1
• Maximum dose: 1.8 mg daily after at least one week at 1.2 mg if further control required 1
• Pharmacokinetic profile in pediatric patients (10-17 years) is consistent with adults 1

Important Safety Monitoring

Contraindications

• Personal or family history of medullary thyroid carcinoma 4
• Multiple endocrine neoplasia type 2 4
• Known hypersensitivity to liraglutide or excipients 2

Monitoring Requirements

• Assess hydration status if taking insulin or sulfonylureas 4
• Monitor for signs/symptoms of pancreatitis or gallbladder disorders 4
• Pancreatitis is a precaution but not an absolute contraindication 4

Common Adverse Effects

• Nausea is the most frequently reported adverse event, occurring in 8-44% depending on dose and indication 4, 2
• Gastrointestinal side effects (nausea, diarrhea, vomiting, constipation) are transient and diminish over time 4, 2, 3
• The gradual weekly titration schedule significantly improves tolerability 2, 3

Special Populations

No Dose Adjustment Required

• Age has no effect on liraglutide pharmacokinetics (studied in patients 18-83 years) 1, 2
• Gender, race, and ethnicity do not necessitate dose modifications 1, 2
• Body weight affects exposure (lower exposure with higher weight), but the standard 1.2 mg and 1.8 mg doses remain appropriate across weight ranges 1

Pharmacokinetic Profile

• Peak concentrations achieved 8-12 hours post-dosing 1
• Elimination half-life approximately 13 hours, supporting once-daily administration 1
• Absolute bioavailability approximately 55% after subcutaneous injection 1